September 21, 2021

Research Proves Feasibility of New Cancer Treatment Approach

Radiation planning technique safely reduces toxicity


Researchers from Cleveland Clinic and OhioHealth have published results from a first-in-human trial evaluating feasibility of Temporally Feathered Radiation Therapy (TFRT), which is designed to reduce the toxicity of radiation treatment.


Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

The research, appearing in Radiotherapy & Oncology, proved TFRT’s feasibility in clinical workflow. Additionally, assessments of treatment toxicities and radiation dosage comparisons to a standard radiotherapy plan were described.

TFRT is a novel technique for the planning and optimization of radiotherapy that considers the nonlinear aspects of normal tissue repair to manage toxicity. The technique is designed to reduce radiation-induced toxicities by optimizing the time through which radiation is delivered and consequently improves normal tissue recovery. Radiation-induced toxicity is a major contributor to impacting a patients’ quality of life and often a dose-limiting factor in the treatment of cancer with radiation therapy.

“We are excited that the complex TFRT technique, which uses current planning systems, was able to be delivered safely and in a standard clinical workflow,” said Jacob G. Scott, M.D., DPhil, a Cleveland Clinic radiation oncologist and the inventor of TFRT. “A larger trial with toxicity as the primary endpoint will allow us to truly study the efficacy of the approach. Collaboration will be important as we work to integrate TFRT into planning systems to expand automation and wider adoption into clinical practice.”


Study specifics

In this study, five patients with head and neck squamous cell carcinoma were treated with TFRT. The primary endpoint was feasibility of TFRT planning as defined by radiation start within 15 days of treatment planning. Secondary endpoints included estimates of toxicity.

The primary endpoint was met when patients were successfully treated with TFRT techniques without causing delays in radiation commencement. For patients who received TFRT, the median time from treatment planning to radiation start was 10 business days – not outside of standard timelines. The average time required for radiation planning was six days. The organs feathered included oral cavity, each submandibular gland, each parotid gland, supraglottis, and posterior pharyngeal wall. There were no significant deviations from standard planning, and toxicity was no more than expected – but we expect a larger trial to show reductions in toxicity without effecting cure rates.

“Radiation oncologists and physicists have made amazing advances in shaping the radiation dose to organs and tissue near a patient’s tumors, leading to effective treatments with less toxicity,” added Shireen Parsai, M.D., a radiation oncologist at OhioHealth who led this research during her residency at Cleveland Clinic. “TFRT takes advantage of the differential repair of tumors vs. healthy tissue by modulating how the dose is delivered to nearby tissue over time. This approach gives normal tissue more time to heal, allowing us, in theory, to deliver the same curative doses of radiation with less detriment to the patient’s quality of life.”


Related Articles

November 22, 2023
A Germline Biomarker Offers Insight Into Treatment Selection for Men With Prostate Cancer

Correlation found between the biomarker HSD3B1 and resistance to combined hormone therapy and radiotherapy

23-CNR-4210973-CQD-Hero-650×450 Dr Mayo
November 2, 2023
Studying Ultra-Hypofractionated Radiotherapy for Soft Tissue Sarcoma

Meta-analysis suggests efficacy and safety

23-CNR-4164208 ASTRO 2023 graphic CQD
September 21, 2023
Top 10 Presentations You Don’t Want to Miss at ASTRO 2023

Highlighting top abstracts for the annual radiation oncology conference

23-CNR-3964459-CQD-Hero-650×450 SBRT
July 5, 2023
New Study Highlights Potential Benefits of Ultrasound-Guided Prostate SBRT

Transperineal ultrasound a viable, non-invasive option for monitoring intra-fractional prostate motion

ASTRO 2022 abstracts
November 4, 2022
Top Research from ASTRO 2022

Key abstracts highlight advances in treating locally advanced and refractory disease

radiation therapy
October 14, 2022
Radiation Oncology-Biology Integration Network (ROBIN) Explores Precision Medicine

Multidisciplinary team to examine radiation therapy combined with immunotherapy

March 17, 2022
Aggressive Daily Radiation in Breast Cancer Survivor with Angiosarcoma: A Case Study

Preoperative treatment ensures successful surgical resection

Squamous Cell carcinoma under microscopy
December 2, 2021
Study Identifies Prognostic Subgroups in Cutaneous Squamous Cell Carcinoma

Modification of traditional staging factors associated with survival in high-risk disease